CDMO/CMO Mid-Year Review: Tracking the Key Moves Thus Far in 2023 DCAT Value Chain Insights Podcast

As we near the mid-year mark, what have been the key moves—mergers and acquisitions, expansions, and new CDMOs entering the market—thus far in 2023? DCAT Value Chain Insights takes an inside look on what is on the industry’s radar. For the text version of this article visit dcatvci.org.

Key topics: (see Chapter Markers in drop down menu in audio player above) 
BaxterLarge-scale biomanufacturing expansions continue Samsung BiologicsLotte BiologicsFujifilm Diosynth BiotechnologiesLonza WuXi BiologicsExpansions in Peptides and Oligonucleotides Ramp UpBachemAgilent TechnologiesWuXi STACordenPharmaNew CDMOs Enter the Market eureKINGNewBiologixAscend Gene & Cell TherapiesPodcast Sponsor: Vetter Pharma International GmbH

Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show  
Support the show
Support the show